Comparative Pharmacology
Head-to-head clinical analysis: ALOXI versus GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOXI versus GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE.
ALOXI vs GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, preventing nausea and vomiting.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at vagal afferents in the gastrointestinal tract and area postrema of the central nervous system, inhibiting emetic reflex.
0.25 mg intravenously over 30 seconds, administered 30 minutes before chemotherapy on day 1 of each cycle; not to be repeated within 7 days.
2 mg orally once daily or 1 mg intravenously twice daily for prevention of chemotherapy-induced nausea and vomiting.
None Documented
None Documented
Clinical Note
moderateRaloxifene + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Fluconazole
Terminal elimination half-life is approximately 40 hours (range 33–45 hours) in adults, allowing once-daily dosing for prevention of chemotherapy-induced nausea and vomiting.
Terminal elimination half-life: 4.1–6.1 hours in healthy adults; prolonged to 7.7–9.2 hours in elderly and in hepatic impairment.
Renal (approximately 50% unchanged drug), biliary/fecal (approximately 35% as metabolites). Total clearance is 160 ± 38 mL/min.
Renal (48% unchanged, 18% as metabolites), fecal (34% as metabolites).
Category C
Category A/B
5-HT3 Antagonist
5-HT3 Antagonist
"The metabolism of Fluconazole can be decreased when combined with Raloxifene."